Anticancer research · 2026
A Prospective Study of Olanzapine and Aprepitant for CINV in Cisplatin-HAIC for Hepatocellular Carcinoma (PROACT).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okuyama Shunsuke, Ueno Masayuki, Oi Takahiro, Nishikawa Satoru, Kato Kenshin, Matsuno Keiko, Sakaue Junya, Tajima Koichiro, Moriwaki Toshikazu, Kayahara Takahisa, Takabatake Hiroyuki, Morimoto Youichi, Mouri Hirokazu, Mizuno Motowo
Аннотация
BACKGROUND/AIM: This study investigated the efficacy and safety of olanzapine and aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with hepatocellular carcinoma (HCC) undergoing cisplatin-based hepatic arterial infusion chemotherapy (HAIC).
PATIENTS AND METHODS: This single-center, non-randomized, prospective study included patients with HCC receiving cisplatin-HAIC between December 2020 and February 2023. In the first treatment session, patients without diabetes mellitus received granisetron and olanzapine (GRA+OLA), and those with diabetes received granisetron monotherapy (GRA). The primary endpoint was the complete response (CR, no vomiting or rescue medications) rate in the GRA+OLA group. In the second session, aprepitant was added if complete control (CC, CR plus no severe nausea) was not achieved during the first treatment. Secondary endpoints were rates of CC and total control (TC, CR plus no nausea), changes in liver function, and toxicity in each medication group.
RESULTS: The CR rate in the GRA+OLA group (n=7) was 85.7% (90% confidence interval=47.9-99.3%), which is numerically but not statistically significantly higher than the rate in the GRA group (n=9, 66.7%; p=0.59). Aprepitant was added in two cases, both of which achieved TC. No grade ≥3 treatment-related adverse events were observed.
CONCLUSION: Olanzapine and/or aprepitant with granisetron may be effective and safe as an antiemetic therapy in cisplatin-HAIC.
PATIENTS AND METHODS: This single-center, non-randomized, prospective study included patients with HCC receiving cisplatin-HAIC between December 2020 and February 2023. In the first treatment session, patients without diabetes mellitus received granisetron and olanzapine (GRA+OLA), and those with diabetes received granisetron monotherapy (GRA). The primary endpoint was the complete response (CR, no vomiting or rescue medications) rate in the GRA+OLA group. In the second session, aprepitant was added if complete control (CC, CR plus no severe nausea) was not achieved during the first treatment. Secondary endpoints were rates of CC and total control (TC, CR plus no nausea), changes in liver function, and toxicity in each medication group.
RESULTS: The CR rate in the GRA+OLA group (n=7) was 85.7% (90% confidence interval=47.9-99.3%), which is numerically but not statistically significantly higher than the rate in the GRA group (n=9, 66.7%; p=0.59). Aprepitant was added in two cases, both of which achieved TC. No grade ≥3 treatment-related adverse events were observed.
CONCLUSION: Olanzapine and/or aprepitant with granisetron may be effective and safe as an antiemetic therapy in cisplatin-HAIC.